Momelotinib (BioDeep_00000858771)
代谢物信息卡片
化学式: C23H22N6O2 (414.18041519999997)
中文名称: Momelotinib
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1COCCN1C2=CC=C(C=C2)NC3=NC=CC(=N3)C4=CC=C(C=C4)C(=O)NCC#N
InChI: InChI=1S/C23H22N6O2/c24-10-12-25-22(30)18-3-1-17(2-4-18)21-9-11-26-23(28-21)27-19-5-7-20(8-6-19)29-13-15-31-16-14-29/h1-9,11H,12-16H2,(H,25,30)(H,26,27,28)
描述信息
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C172200 - JAK Inhibitor
D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors
同义名列表
2 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:91407
- KEGGdrug: D10315
- PubChem: 25062766
- DrugBank: DB11763
- ChEMBL: CHEMBL1078178
- CAS: 1056634-68-4
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Helen T Chifotides, Prithviraj Bose, Srdan Verstovsek. Momelotinib: an emerging treatment for myelofibrosis patients with anemia.
Journal of hematology & oncology.
2022 01; 15(1):7. doi:
10.1186/s13045-021-01157-4. [PMID: 35045875] - David A Barbie, Alexander Spira, Karen Kelly, Rita Humeniuk, Jun Kawashima, Shengchun Kong, Marianna Koczywas. Phase 1B Study of Momelotinib Combined With Trametinib in Metastatic, Kirsten Rat Sarcoma Viral Oncogene Homolog-Mutated Non-Small-Cell Lung Cancer After Platinum-Based Chemotherapy Treatment Failure.
Clinical lung cancer.
2018 11; 19(6):e853-e859. doi:
10.1016/j.cllc.2018.07.004. [PMID: 30087028] - Yan Xin, Jun Kawashima, Winnie Weng, Ellen Kwan, Thomas Tarnowski, Jeffrey A Silverman. Pharmacokinetics and Safety of Momelotinib in Subjects With Hepatic or Renal Impairment.
Journal of clinical pharmacology.
2018 04; 58(4):522-532. doi:
10.1002/jcph.1050. [PMID: 29283448] - Jim Zheng, Yan Xin, Jingyu Zhang, Raju Subramanian, Bernard P Murray, J Andrew Whitney, Matthew R Warr, John Ling, Lisa Moorehead, Ellen Kwan, Jeffrey Hemenway, Bill J Smith, Jeffrey A Silverman. Pharmacokinetics and Disposition of Momelotinib Revealed a Disproportionate Human Metabolite-Resolution for Clinical Development.
Drug metabolism and disposition: the biological fate of chemicals.
2018 03; 46(3):237-247. doi:
10.1124/dmd.117.078899. [PMID: 29311136] - Yan Xin, Lixin Shao, Julie Maltzman, Dimitrios Stefanidis, Jeffrey Hemenway, Thomas Tarnowski, Wei Deng, Jeffrey A Silverman. The Relative Bioavailability, Food Effect, and Drug Interaction With Omeprazole of Momelotinib Tablet Formulation in Healthy Subjects.
Clinical pharmacology in drug development.
2018 03; 7(3):277-286. doi:
10.1002/cpdd.397. [PMID: 29024542] - Hui-Wen Lue, Jennifer Podolak, Kevin Kolahi, Larry Cheng, Soumya Rao, Devin Garg, Chang-Hui Xue, Juha K Rantala, Jeffrey W Tyner, Kent L Thornburg, Ann Martinez-Acevedo, Jen-Jane Liu, Christopher L Amling, Charles Truillet, Sharon M Louie, Kimberly E Anderson, Michael J Evans, Valerie B O'Donnell, Daniel K Nomura, Justin M Drake, Anna Ritz, George V Thomas. Metabolic reprogramming ensures cancer cell survival despite oncogenic signaling blockade.
Genes & development.
2017 10; 31(20):2067-2084. doi:
10.1101/gad.305292.117. [PMID: 29138276] - Srdan Verstovsek, Stephane Courby, Martin Griesshammer, Ruben A Mesa, Carrie Baker Brachmann, Jun Kawashima, Julia D Maltzman, Lixin Shao, Yan Xin, Daniel Huang, Ashish Bajel. A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia.
Leukemia research.
2017 09; 60(?):11-17. doi:
10.1016/j.leukres.2017.05.002. [PMID: 28622623] - Hui-Wen Lue, Brook Cole, Soumya A M Rao, Jennifer Podolak, Ahna Van Gaest, Carly King, Christopher A Eide, Beth Wilmot, Changhui Xue, Paul T Spellman, Laura M Heiser, Jeffrey W Tyner, George V Thomas. Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma.
Oncotarget.
2015 Dec; 6(42):44675-87. doi:
10.18632/oncotarget.5971. [PMID: 26625308] - S Durmus, N Xu, R W Sparidans, E Wagenaar, J H Beijnen, A H Schinkel. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.
Pharmacological research.
2013 Oct; 76(?):9-16. doi:
10.1016/j.phrs.2013.06.009. [PMID: 23827160] - A Pardanani, R R Laborde, T L Lasho, C Finke, K Begna, A Al-Kali, W J Hogan, M R Litzow, A Leontovich, M Kowalski, A Tefferi. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis.
Leukemia.
2013 Jun; 27(6):1322-7. doi:
10.1038/leu.2013.71. [PMID: 23459451] - Rolf W Sparidans, Selvi Durmus, Ning Xu, Alfred H Schinkel, Jan H M Schellens, Jos H Beijnen. Liquid chromatography-tandem mass spectrometric assay for the JAK2 inhibitor CYT387 in plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2012 May; 895-896(?):174-7. doi:
10.1016/j.jchromb.2012.03.021. [PMID: 22476054] - Rolf W Sparidans, Selvi Durmus, Ning Xu, Alfred H Schinkel, Jan H M Schellens, Jos H Beijnen. Liquid chromatography-tandem mass spectrometric assay for the VEGFR inhibitor cediranib and its primary human metabolite cediranib-N⁺-glucuronide in plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2012 May; 895-896(?):169-73. doi:
10.1016/j.jchromb.2012.03.020. [PMID: 22476055]